Peptides identified in 3 patients
| Source . | Eluted at (% Actonitril) . | Sequence . | Protein Source . | Residues . | Yield (pmol) . | Mass (Found./Theor.) . |
|---|---|---|---|---|---|---|
| P1 | 30.2, 32.8 | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | HNP-1 | 65-94 | 45, 32 | 3454.4/3439.5 |
| P1 | 30.2, 31.2 | CYCRIPACIAGERRYGTCIYQGRLWAFCC | HNP-2 | 66-94 | 45, 32 | 3383.4/3368.4 |
| P1 | 31.2 | NMACYCRIPACIAGERRYGTCIYQGRLWAFCC | pre-HNP-1 | 63-94 | 20 | 3705.4/3684.6 |
| P1 | 31.2, 32.0 | SLAWDESLAPKHPGSRKNMACYCRIPACIAGERRYGTCIYQGRLWAFCC | pre-HNP-1 | 46-94 | 35, 16 | 5554.4/5544.5 |
| P1 | 23.2 | XPVFYVGPEXQI … | Unknown | ? | 15 | 3188.4/? |
| P1 | 28.4 | LPKPPKPVSKMRMATPLLMQALPMGALPQGPMQNATKYGNMTE | CLIP | 80-122 | 20 | 4657.9/4666.7 |
| P1 | 35.3 | LPKPPKPVSKMRMATPLLMQALP | CLIP | 80-102 | 15 | 2557.5/2545.3 |
| P1 | 35.3 | KDVALSVLSKDLTDMD … | CDC27HS | 548-? | 10 | nd |
| P1 | 35.7 | PKPPKPVSKMRMATPLLMQALPM | CLIP | 81-103 | 8 | 2564.9/2563.3 |
| P1 | 36.8 | VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD | HNP-4 | 64-97 | 18 | 3818.6/3821.3 |
| P1 | 37.7 | LPKPPKPVSKMRMATPLLMQALPM | CLIP | 80-103 | 12 | 2679.9/2676.5 |
| P2 | 30.0 | ACYCRIAPACIAGERRYGTCIYQGRLWAFCC | HNP-1 | 65-94 | 20 | 3426.3/3439.5 |
| P2 | 30.0, 30.5 | CYCRIAPACIAGERRYGTCIYQGRLWAFCC | HNP-2 | 66-94 | 20, 17 | 3357.6/3368.4 |
| P2 | 30.5 | VLPKLYVKLHYCVSVSCVIHSKV … | Rib prot S26 | 63-? | 25 | nd |
| P2 | 32.8, 36.0, 36.2 | DIPEVVVSLAWDESLAPKHPGSRKNMACY … | pre-HNP-1 | 39-? | 40, 5, 8 | nd |
| P2 | 30.5, 40.5 | VLSPADKTNVKAAWGKVGAH | hemoglobin α | 1-? | 18, 15 | nd |
| CML | 29.9 | ACYCRIPACIAGERRY … | HNP-1 | 65-? | nd | nd |
| CML | 29.9 | CYCRIPACIAGERRY … | HNP-2 | 66-? | nd | nd |
| Source . | Eluted at (% Actonitril) . | Sequence . | Protein Source . | Residues . | Yield (pmol) . | Mass (Found./Theor.) . |
|---|---|---|---|---|---|---|
| P1 | 30.2, 32.8 | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | HNP-1 | 65-94 | 45, 32 | 3454.4/3439.5 |
| P1 | 30.2, 31.2 | CYCRIPACIAGERRYGTCIYQGRLWAFCC | HNP-2 | 66-94 | 45, 32 | 3383.4/3368.4 |
| P1 | 31.2 | NMACYCRIPACIAGERRYGTCIYQGRLWAFCC | pre-HNP-1 | 63-94 | 20 | 3705.4/3684.6 |
| P1 | 31.2, 32.0 | SLAWDESLAPKHPGSRKNMACYCRIPACIAGERRYGTCIYQGRLWAFCC | pre-HNP-1 | 46-94 | 35, 16 | 5554.4/5544.5 |
| P1 | 23.2 | XPVFYVGPEXQI … | Unknown | ? | 15 | 3188.4/? |
| P1 | 28.4 | LPKPPKPVSKMRMATPLLMQALPMGALPQGPMQNATKYGNMTE | CLIP | 80-122 | 20 | 4657.9/4666.7 |
| P1 | 35.3 | LPKPPKPVSKMRMATPLLMQALP | CLIP | 80-102 | 15 | 2557.5/2545.3 |
| P1 | 35.3 | KDVALSVLSKDLTDMD … | CDC27HS | 548-? | 10 | nd |
| P1 | 35.7 | PKPPKPVSKMRMATPLLMQALPM | CLIP | 81-103 | 8 | 2564.9/2563.3 |
| P1 | 36.8 | VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD | HNP-4 | 64-97 | 18 | 3818.6/3821.3 |
| P1 | 37.7 | LPKPPKPVSKMRMATPLLMQALPM | CLIP | 80-103 | 12 | 2679.9/2676.5 |
| P2 | 30.0 | ACYCRIAPACIAGERRYGTCIYQGRLWAFCC | HNP-1 | 65-94 | 20 | 3426.3/3439.5 |
| P2 | 30.0, 30.5 | CYCRIAPACIAGERRYGTCIYQGRLWAFCC | HNP-2 | 66-94 | 20, 17 | 3357.6/3368.4 |
| P2 | 30.5 | VLPKLYVKLHYCVSVSCVIHSKV … | Rib prot S26 | 63-? | 25 | nd |
| P2 | 32.8, 36.0, 36.2 | DIPEVVVSLAWDESLAPKHPGSRKNMACY … | pre-HNP-1 | 39-? | 40, 5, 8 | nd |
| P2 | 30.5, 40.5 | VLSPADKTNVKAAWGKVGAH | hemoglobin α | 1-? | 18, 15 | nd |
| CML | 29.9 | ACYCRIPACIAGERRY … | HNP-1 | 65-? | nd | nd |
| CML | 29.9 | CYCRIPACIAGERRY … | HNP-2 | 66-? | nd | nd |
Listing of HLA-DR-bound endogenous peptides from different sources. The retention times of the two plasmacytoma patient-derived fractions are comparable. Different acetonitrile gradients were used for the HPLC separation of the different experiments (see “Materials and methods”). To compare the corresponding elution times of each peptide, the calculated percentage of acetonitrile is indicated. Sequences were determined by micro-Edman sequencing, masses were determined by MALDI-MS and ESI-MS and the peptide lengths calculated. Some fractions were not submitted to mass spectrometry and therefore the C-terminus of the peptide was not detected.
CLIP indicates class II-associated invariant chain peptides; CML, chronic myeloid leukemia; ESI-MS, electrospray ionization mass spectrometry; HNP, human neutrophil peptide; HPLC, high-performance liquid chromatography; MALDI-MS, matrix-assisted laser desorption mass spectrometry; nd, not determined; P1, plasmacytoma patient 1; P2, plasmacytoma patient 2.